CEL-SCI Corporation news

   Watch this stock
Showing stories 21 - 30 of about 88   

Articles published

CVM 1.89 +0.09 (4.70%)
price chart
CEL-SCI Gives Update on Partial Clinical Hold on Phase 3 Head and Neck Cancer ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) announces that it has received the official minutes from its February 8, 2017 meeting with the U.S.
CEL-SCI Corporation (NYSEMKT:CVM) Addresses FDA Partial Clinical Hold  Small Cap Exclusive (press release)
CEL-SCI Announces Update on Arbitration against Former Clinical Research ...
Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving ...
Vanguard Group Inc built an about 0.93% stake in CEL-SCI Corporation (CVM)  Post Analyst
Cel-Sci Is Closer To The Finish Line, But Skip This Stock For Now
Cel-Sci Corporation (NYSEMKT:CVM), a micro-cap biotechnology company, reported financial results for the fiscal first quarter (FQ1) ended December 31, 2014 on February 6. The company is involved in the research and development (R&D) of immunotherapy ...
FDA places CEL-SCI's late-stage Multikine study in head and neck cancer on ...
The FDA has notified CEL-SCI (NYSEMKT:CVM) that its Phase 3 clinical trial assessing Multikine (Leukocyte Interleukin, Injection) for the treatment of head and neck cancer is on full clinical hold, meaning that all dosing must cease immediately.
CEL-SCI Corporation (CVM) Stock: Takes A Dive On FDA Clinical Hold  CNA Finance (press release)
CEL-SCI Announces New Data for Its Rheumatoid Arthritis Vaccine Candidate ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) announces the publication of data from rheumatoid arthritis (RA) studies in Vaccine, a leading peer-reviewed journal for researchers interested in vaccines and vaccination.
CEL-SCI's Manufacturing Of Cancer-Killer Multikine Marks A World-Class Facility
Deep in the state of Maryland, home of the coveted blue crab and picturesque Chesapeake Bay, stands CEL-SCI's (NYSEMKT:CVM) 75,000-square-foot manufacturing facility for Multikine, its exceptional immune-boosting drug geared toward head and neck cancer ...
CEL-SCI Announces Change to the Date of Its Annual Meeting
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) today announced it has changed the date for its annual meeting from June 9, 2017 to June 12, 2017.
CEL-SCI Corp (CVM) Prices $4.25M Common Stock, Warrants Offering
CEL-SCI Corporation (NYSE: CVM) announced that it has priced its public offering of common stock and warrants. CEL-SCI announced that it has agreed to sell 34,024,000 shares of common stock and warrants to purchase common stock at a price of $0.125 ...
CEL-SCI Announces Pricing of $4.25 Million Public Offering of Common Stock ...  Business Wire (press release)
Interesting Developments For Cel-Sci's Upcoming Court-Date With Its Former CRO ...
Cel-Sci Corporation (NYSEMKT:CVM), is a clinical stage bio-pharma company with a lead drug candidate (Multikine´┐Ż) currently in the process of a long and slowly populated Phase III study for its effectiveness as a supplemental treatment for Head and ...
Should You Invest In The Healthcare Stock CEL-SCI Corporation (CVM)?
CEL-SCI Corporation (AMEX:CVM), a USD$21.53M small-cap, is a healthcare company operating in an industry, which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasing prevalence of diseases and ...